FierceBiotechOriginal article
{"a":[{"_":"Tarsus pays $450M for Alkeus and its phase 3-stage retinal disease drug","$":{"href":"/biotech/tarsus-stakes-450m-alkeus-phase-3-retinal-disease-drug","hreflang":"en"}}]}
Positive
AI Analysis
Summary
Tarsus Pharmaceuticals announced the acquisition of Alkeus Pharmaceuticals for $450 million to obtain a phase 3-stage retinal disease therapy with blockbuster potential.
Clinical Trial Data
Phase
Phase 3
Importance:7/10
Sentiment:
0.60
M&APhase 3retinal diseaseblockbuster potential
Related Companies
Read the original article
Published by FierceBiotech on August 6, 2026 10:07 AM
